With MicroPulse®, a continuous-wave laser beam is chopped into a train of tiny, repetitive, low energy pulses separated by a brief rest period which allows the tissue to cool between laser pulses. MicroPulse® laser therapy also can be used in conjunction with drug therapy, allowing complete and optimized management of retinal diseases and glaucoma without laser-induced damage.
MicroPulse® settings extend the aspects of tissue-sparing applications to treatments otherwise performed with conventional photocoagulation. DME, CSR, and even PDR are areas where MicroPulse® laser therapy can be utilised.
MicroPulse® laser trabeculoplasty (MLT) is a tissue-sparing laser therapy intended to reduce intraocular pressure. Unlike conventional laser trabeculoplasty procedures, there is no destructive, coagulative damage to the trabecular meshwork.
MicroPulse® allows the tissue to cool between laser pulses, minimizing or preventing tissue damage. Treatment risks are reduced or eliminated, with increased patient comfort than with conventional, continuous-wave laser treatment.
MicroPulse® can be used with the IQ532, IQ577 & IQ810 lasers.
IRIDEX Corporation is the patent holder of MicroPulse® Technology and the only manufacturer of infrared and visible laser systems with this proprietary technology.